Understanding resistance to combination chemotherapy

Abeloff, 2008 Abramson, 2005, Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach, Blood, 106, 1164, 10.1182/blood-2005-02-0687 Almeida Da Silva, 2011, Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs, Journal of Antimicrobial Chemotherapy, 66, 1417, 10.1093/jac/dkr173 Anastassiadis, 2011, Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity, Nature Biotechnology, 29, 1039, 10.1038/nbt.2017 Bantscheff, 2007, Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors, Nature Biotechnology, 25, 1035, 10.1038/nbt1328 Bantscheff, 2011, Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes, Nature Biotechnology, 29, 255, 10.1038/nbt.1759 Bartz, 2006, Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions, Molecular and Cellular Biology, 26, 9377, 10.1128/MCB.01229-06 Beketic-Oreskovic, 1995, Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833, Journal of the National Cancer Institute, 87, 1593, 10.1093/jnci/87.21.1593 Bledsoe, 2002, Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition, Cell, 110, 93, 10.1016/S0092-8674(02)00817-6 Borst, 2012, Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?, Open Biology, 2, 120066, 10.1098/rsob.120066 Borst, 2007, What makes tumors multidrug resistant?, Cell Cycle, 6, 2782, 10.4161/cc.6.22.4936 Boulos, 2011, Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia, Blood, 117, 3585, 10.1182/blood-2010-08-301267 Campillos, 2008, Drug target identification using side-effect similarity, Science, 321, 263, 10.1126/science.1158140 Chabner, 2005, Timeline: chemotherapy and the war on cancer, Nature Reviews Cancer, 5, 65, 10.1038/nrc1529 Chen, 2009, Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data, Molecular Systems Biology, 5, 239, 10.1038/msb.2008.74 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, The New England Journal of Medicine, 364, 1817, 10.1056/NEJMoa1011923 DeVita, 1973, The use of drugs in combination for the treatment of cancer: rationale and results, The New England Journal of Medicine, 288, 998, 10.1056/NEJM197305102881905 Ding, 2012, Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing, Nature, 481, 506, 10.1038/nature10738 Doles, 2010, Nek4 status differentially alters sensitivity to distinct microtubule poisons, Cancer Research, 70, 1033, 10.1158/0008-5472.CAN-09-2113 Dudley, 2011, Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease, Science Translational Medicine, 3, ra76, 10.1126/scitranslmed.3002648 Durant, 1999, Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial, Lancet, 353, 2195, 10.1016/S0140-6736(98)12291-2 Erler, 2010, Network-based drugs and biomarkers, Journal of Pathology, 220, 290, 10.1002/path.2646 Farber, 1948, Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid, The New England Journal of Medicine, 238, 787, 10.1056/NEJM194806032382301 Fitzgerald, 2006, Systems biology and combination therapy in the quest for clinical efficacy, Nature Chemical Biology, 2, 458, 10.1038/nchembio817 Frei, 1958, A comparative study of two regimens of combination chemotherapy in acute leukemia, Blood, 13, 1126, 10.1182/blood.V13.12.1126.1126 Freireich, 1964, Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood Goodman, 1984, Landmark article Sept. 21, 1946: nitrogen mustard therapy, vol. 251, 2255 Hashimoto, 1996, A comparison of the propensity for gene amplification between near-tetraploid and near-diploid V79 clones resistant to 150nM methotrexate, Carcinogenesis, 17, 389, 10.1093/carcin/17.3.389 Hieronymus, 2006, Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators, Cancer Cell, 10, 321, 10.1016/j.ccr.2006.09.005 Janes, 2005, A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis, Science, 310, 1646, 10.1126/science.1116598 Janes, 2004, Cue-signal-response analysis of TNF-induced apoptosis by partial least squares regression of dynamic multivariate data, Journal of Computational Biology, 11, 544, 10.1089/cmb.2004.11.544 Jiang, 2011, A mammalian functional-genetic approach to characterizing cancer therapeutics, Nature Chemical Biology, 7, 92, 10.1038/nchembio.503 Kantarjian, 2012, Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION), Blood, 119, 1123, 10.1182/blood-2011-08-376087 Karaman, 2008, A quantitative analysis of kinase inhibitor selectivity, Nature Biotechnology, 26, 127, 10.1038/nbt1358 Kreeger, 2010, Cancer systems biology: a network modeling perspective, Carcinogenesis, 31, 2, 10.1093/carcin/bgp261 Kreeger, 2009, RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects, Cancer Research, 69, 8191, 10.1158/0008-5472.CAN-09-1921 Kumar, 2008, Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells, Molecular Pharmacology, 73, 1668, 10.1124/mol.107.043794 Lamb, 2006, The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease, Science, 313, 1929, 10.1126/science.1132939 Law, 1952, Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice, Cancer Research, 12, 871 Law, 1952, Origin of the resistance of leukaemic cells to folic acid antagonists, Nature, 169, 628, 10.1038/169628a0 Lee, 2007, A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery, Proceedings of the National Academy of Sciences of the United States of America, 104, 13086, 10.1073/pnas.0610292104 Letai, 2008, Diagnosing and exploiting cancer's addiction to blocks in apoptosis, Nature Reviews Cancer, 8, 121, 10.1038/nrc2297 Luria, 1943, Mutations of bacteria from virus sensitivity to virus resistance, Genetics, 28, 491, 10.1093/genetics/28.6.491 Matthews, 1977, Dihydrofolate reductase: X-ray structure of the binary complex with methotrexate, Science, 197, 452, 10.1126/science.17920 Miller-Jensen, 2007, Common effector processing mediates cell-specific responses to stimuli, Nature, 448, 604, 10.1038/nature06001 Mullighan, 2008, Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia, Science, 322, 1377, 10.1126/science.1164266 Mullighan, 2011, CREBBP mutations in relapsed acute lymphoblastic leukaemia, Nature, 471, 235, 10.1038/nature09727 Newcombe, 1949, Spontaneous mutation to streptomycin resistance and dependence in Escherichia coli, Journal of Bacteriology, 57, 565, 10.1128/JB.57.5.565-572.1949 Ni Chonghaile, 2011, Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy, Science, 334, 1129, 10.1126/science.1206727 Paull, 1989, Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm, Journal of the National Cancer Institute, 81, 1088, 10.1093/jnci/81.14.1088 Pawson, 2008, Network medicine, FEBS Letters, 582, 1266, 10.1016/j.febslet.2008.02.011 Pirker, 2009, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9 Pommier, 2010, DNA topoisomerases and their poisoning by anticancer and antibacterial drugs, Chemistry and Biology, 17, 421, 10.1016/j.chembiol.2010.04.012 Scherf, 2000, A gene expression database for the molecular pharmacology of cancer, Nature Genetics, 24, 236, 10.1038/73439 Schoeberl, 2009, Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis, Science Signaling, 2, ra31, 10.1126/scisignal.2000352 Shah, 2007, Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency, The Journal of Clinical Investigation, 117, 2562, 10.1172/JCI30890 Shah, 2004, Overriding imatinib resistance with a novel ABL kinase inhibitor, Science, 305, 399, 10.1126/science.1099480 Sirota, 2011, Discovery and preclinical validation of drug indications using compendia of public gene expression data, Science Translational Medicine, 3, ra77, 10.1126/scitranslmed.3001318 Skipper, 1964, Experimental evaluation of potential anticancer agents, Xiii. On the criteria and kinetics associated with “curability” of experimental leukemia, Cancer Chemotherapy Reports. Part 1, 35, 1 Skipper, 1954, Attempts at dual blocking of biochemical events in cancer chemotherapy, Cancer Research, 14, 503 Staker, 2002, The mechanism of topoisomerase I poisoning by a camptothecin analog, Proceedings of the National Academy of Sciences of the United States of America, 99, 15387, 10.1073/pnas.242259599 Szakacs, 2006, Targeting multidrug resistance in cancer, Nature Reviews Drug Discovery, 5, 219, 10.1038/nrd1984 Talpaz, 2006, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias, The New England Journal of Medicine, 354, 2531, 10.1056/NEJMoa055229 Tentner, 2012, Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress, Molecular Systems Biology, 8, 568, 10.1038/msb.2012.1 Toettcher, 2009, Distinct mechanisms act in concert to mediate cell cycle arrest, Proceedings of the National Academy of Sciences of the United States of America, 106, 785, 10.1073/pnas.0806196106 Turke, 2010, Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC, Cancer Cell, 17, 77, 10.1016/j.ccr.2009.11.022 Wagle, 2011, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 3085, 10.1200/JCO.2010.33.2312 Wall, 1995, Camptothecin and taxol: discovery to clinic–thirteenth Bruce F. Cain Memorial Award Lecture, Cancer Research, 55, 753 Wei, 2006, Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance, Cancer Cell, 10, 331, 10.1016/j.ccr.2006.09.006 Weinstein, 1997, An information-intensive approach to the molecular pharmacology of cancer, Science, 275, 343, 10.1126/science.275.5298.343 Whitehurst, 2007, Synthetic lethal screen identification of chemosensitizer loci in cancer cells, Nature, 446, 815, 10.1038/nature05697 Wolpaw, 2011, Modulatory profiling identifies mechanisms of small molecule-induced cell death, Proceedings of the National Academy of Sciences of the United States of America, 108, E771, 10.1073/pnas.1106149108 Xie, 2012, Novel computational approaches to polypharmacology as a means to define responses to individual drugs, Annual Review of Pharmacology and Toxicology, 52, 361, 10.1146/annurev-pharmtox-010611-134630 Yauch, 2009, Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma, Science, 326, 572, 10.1126/science.1179386 Zander, 2010, Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan, Cancer Research, 70, 1700, 10.1158/0008-5472.CAN-09-3367 Zhang, 2010, Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors, Nature, 463, 501, 10.1038/nature08675